Can a Racial Divide Explain Non-Treatment of HCV among the HIV-HCV Coinfected?

BY JENNIFER G. ALLEN
Study finds a common assortment of reasons for non-initiation of HCV therapy, regardless of patient race or ethnicity.
PUBLISHED MONDAY, APRIL 11, 2016
These observations were made in the context of interferon-based regimens, although the authors believe that addressing the same barriers can be useful in the era of first-line DAA regimens.

Recommended Articles
Managing the risk of hepatitis C and liver disease among infants born to mothers with chronic HCV is a challenge.
HCV patients with cirrhosis and severe sepsis face elevated risk of organ failure.
Anti-retroviral drug therapy may effectively treat hepatitis C-HIV coinfection.
Antiviral therapies are changing the clinical landscape for the treatment of HCV in developed countries.
Patient access to curative hepatitis C medications remains a challenge.
$auto_registration$